Connect your AI

Anika Therapeutics ANIK Stock-Based Comp

Stock-Based Comp at other companies

StrykerSYK

$87M+3.6%

VericelVCEL

$11.29M-1.8%

Zimmer Biomet HoldingsZBH

$24.2M+23.5%

Pacira BioSciences, Inc.PCRX

$13.54M-7.0%

BioventusBVS

$3.26M+35.2%

Xtant Medical HoldingsXTNT

$746K-1.6%

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's stock-based comp?: Anika Therapeutics (ANIK) reported stock-based comp of $6.64M in Q1 2026.
How has Anika Therapeutics's stock-based comp changed year-over-year?: Anika Therapeutics's stock-based comp increased by 132.0% year-over-year, from $2.86M to $6.64M.
What is the long-term trend for Anika Therapeutics's stock-based comp?: Over 4 years (2021 to 2025), Anika Therapeutics's stock-based comp has grown at a -2.3% compound annual growth rate (CAGR), from $11.09M to $10.08M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.